Income Statement
NUVECTIS PHARMA, INC.
NVCT
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Revenue
|
- | - | - | - |
|
Cost of Revenue
|
- | - | - | - |
|
Gross Profit
|
- | - | - | - |
|
Operating Expenses
|
27.57 | 19.85 | 22.90 | 19.23 |
|
Research & Development
|
18.15 | 12.92 | 15.38 | 13.23 |
|
Selling, General & Administrative
|
9.42 | 6.93 | 7.52 | 6.01 |
|
Other Operating Expenses
|
- | - | - | - |
|
Operating Income
|
-27.57 | -19.85 | -22.90 | -19.23 |
|
Non-Operating Income
|
- | - | - | - |
|
Interest Income
|
- | - | - | - |
|
Interest Expense
|
- | - | - | - |
|
Other Non-Op Income / Expense
|
- | - | - | - |
|
Income Before Tax
|
- | - | - | - |
|
Income Tax Expense
|
- | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - |
|
Net Income
|
-26.44 | -19.00 | -22.26 | -19.09 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY |
|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - |
|
EBITDA
|
-27.57 | -19.85 | -22.90 | -19.23 |
|
Earnings Per Share (Basic)
|
-1.32 | -1.11 | -1.43 | -1.51 |
|
Diluted EPS
|
-1.32 | -1.11 | -1.43 | -1.51 |
|
Weighted Average Shares
|
21.81 | 17.11 | 15.56 | 12.66 |
|
Diluted Weighted Avg Shares
|
21.81 | 17.11 | 15.56 | 12.66 |
|
Comprehensive Income
|
- | - | - | - |